Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously …
Importance Interim analyses of the IMmotion151 trial (A Study of Atezolizumab in
Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced …
Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced …
Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination …
C Riveros, S Ranganathan, J Xu, C Chang… - … Oncology: Seminars and …, 2023 - Elsevier
Introduction While there are a plethora of studies supporting novel treatment approaches in
metastatic clear cell renal cell carcinoma (ccRCC), much of the data used to inform care of …
metastatic clear cell renal cell carcinoma (ccRCC), much of the data used to inform care of …
Biomarkers of prognosis and efficacy of anti-angiogenic therapy in metastatic clear cell renal cancer
C D'Aniello, M Berretta, C Cavaliere, S Rossetti… - Frontiers in …, 2019 - frontiersin.org
In the last decades, the prognosis of metastatic renal cell carcinoma (mRCC) has
remarkably improved following the advent of the “targeted therapy” era. The expanding …
remarkably improved following the advent of the “targeted therapy” era. The expanding …
New approaches to first-line treatment of advanced renal cell carcinoma
The treatment of patients with renal cell carcinoma (RCC) is evolving rapidly, with promising
new regimens being developed and approved for patients with advanced disease …
new regimens being developed and approved for patients with advanced disease …
Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: current paradigms, use of immunotherapy, and future directions
AKA Lalani, BA McGregor, L Albiges, TK Choueiri… - European urology, 2019 - Elsevier
Context Systemic therapy for metastatic clear cell renal cell carcinoma (mccRCC) has
greatly evolved over the last 15 yr. More recently, combination strategies involving …
greatly evolved over the last 15 yr. More recently, combination strategies involving …
LITESPARK-022: A phase 3 study of pembrolizumab+ belzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC).
TK Choueiri, J Bedke, JA Karam, RR McKay, RJ Motzer… - 2022 - ascopubs.org
TPS4602 Background: Patients with locally advanced renal cell carcinoma (RCC) may
experience recurrence after surgery. In the phase 3 KEYNOTE-564 (NCT03142334) trial …
experience recurrence after surgery. In the phase 3 KEYNOTE-564 (NCT03142334) trial …
Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study
Previous analyses of KEYNOTE-426, an open-label, phase 3 randomized study, showed
superior efficacy of first-line pembrolizumab plus axitinib to sunitinib in advanced clear cell …
superior efficacy of first-line pembrolizumab plus axitinib to sunitinib in advanced clear cell …
Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma
Background Immune checkpoint inhibitor/tyrosine kinase inhibitor (ICI/TKI) combinations are
a new standard of care for the initial treatment of metastatic renal cell carcinoma (mRCC) …
a new standard of care for the initial treatment of metastatic renal cell carcinoma (mRCC) …
[HTML][HTML] Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
RJ Motzer, TK Choueiri, DF McDermott… - … for ImmunoTherapy of …, 2022 - ncbi.nlm.nih.gov
Background The phase 3 CheckMate 214 trial demonstrated higher response rates and
improved overall survival with nivolumab plus ipilimumab versus sunitinib in first-line …
improved overall survival with nivolumab plus ipilimumab versus sunitinib in first-line …
CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated …
TPS4578 Background: Therapeutic options have improved outcomes for patients (pts) with
metastatic renal cell carcinoma (mRCC). Nivolumab, a fully human IgG4 programmed cell …
metastatic renal cell carcinoma (mRCC). Nivolumab, a fully human IgG4 programmed cell …